Skip to content

KUVATRIS THERAPEUTICS, INC.

CIK 0001811623

Revenue (TTM)
$0
Q3 Jan 2026
Net Income (TTM)
−$12.62M
−23.6% YoY Q3 Jan 2026
EPS Diluted (TTM)
−$6.19
+61.8% YoY Q3 Jan 2026
Gross Margin
Q3 Jan 2026
Operating Margin
Q3 Jan 2026
Net Margin
Q3 Jan 2026
Free Cash Flow (TTM)
Q3 Jan 2026
Cash
$3.99M
Q3 Jan 2026
Total Debt
Q3 Jan 2026
Shares Outstanding
126.26M sh
Q3 Jan 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings